Correction: Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights [Yahoo! Finance]
Nkarta, Inc. (NKTX)
Company Research
Source: Yahoo! Finance
Preliminary clinical data from Ntrust-1 and Ntrust-2 clinical trials planned for 2025 Cash balance of $426.7 million on June 30, 2024, including cash, cash equivalents and investments, expected to fund operations into late 2027 This press release was updated to reflect the correct dosing schedule of the NKX019 investigator-sponsored clinical trial. As previously disclosed, patients enrolled in this trial will receive three doses of NKX019 on Days 0, 7, and 14. SOUTH SAN FRANCISCO, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today reported financial results for the second quarter ended June 30, 2024. “Patients remain our focus, and early execution on our clinical trials across disease areas is a testament to that commitment,” said Paul J. Hastings, CEO of Nkarta. “NKX019 has the potential to reach people living with a wide range of autoimmune diseases
Show less
Read more
Impact Snapshot
Event Time:
NKTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NKTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NKTX alerts
High impacting Nkarta, Inc. news events
Weekly update
A roundup of the hottest topics
NKTX
News
- Nkarta to Participate in Upcoming Investor ConferenceGlobeNewswire
- Nkarta, Inc. (NASDAQ: NKTX) had its price target lowered by analysts at HC Wainwright from $23.00 to $22.00. They now have a "buy" rating on the stock.MarketBeat
- Why Nkarta Stock Is Soaring Today [Yahoo! Finance]Yahoo! Finance
- Nkarta, Inc. (NASDAQ: NKTX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $13.00 price target on the stock.MarketBeat
- Nkarta, Inc. (NASDAQ: NKTX) was upgraded by analysts at Raymond James from an "outperform" rating to a "strong-buy" rating. They now have a $16.00 price target on the stock.MarketBeat
NKTX
Earnings
- 8/13/24 - Beat
NKTX
Sec Filings
- 8/23/24 - Form 4
- 8/16/24 - Form 8-K/A
- 8/13/24 - Form 10-Q
- NKTX's page on the SEC website